Literature DB >> 21672045

Emerging moulds: epidemiological trends and antifungal resistance.

Marisa H Miceli1, Samuel A Lee.   

Abstract

Invasive fungal infections (IFIs) are associated with high morbidity and mortality in immunocompromised patients. Although Aspergillus spp. remain an important cause of IFI, other moulds such as Fusarium spp., dematiaceous fungi and Mucorales have become increasingly prevalent among this patient population. Diagnosis and treatment of invasive mould infections remain a challenge. Because of the poor prognosis associated with IFIs, understanding the activity, efficacy and limitations of the available drugs is critical to select the appropriate antifungal agent on an individualised basis.
© 2011 Blackwell Verlag GmbH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21672045     DOI: 10.1111/j.1439-0507.2011.02032.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  32 in total

1.  Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.

Authors:  Mariana Castanheira; Shawn A Messer; Paul R Rhomberg; Rachel R Dietrich; Ronald N Jones; Michael A Pfaller
Journal:  Mycopathologia       Date:  2014-06-21       Impact factor: 2.574

2.  Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of molds of the Fusarium genus.

Authors:  David Triest; Dirk Stubbe; Koen De Cremer; Denis Piérard; Anne-Cécile Normand; Renaud Piarroux; Monique Detandt; Marijke Hendrickx
Journal:  J Clin Microbiol       Date:  2014-11-19       Impact factor: 5.948

Review 3.  Identification of Molds by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.

Authors:  Maurizio Sanguinetti; Brunella Posteraro
Journal:  J Clin Microbiol       Date:  2016-11-02       Impact factor: 5.948

Review 4.  MALDI-TOF mass spectrometry: any use for Aspergilli?

Authors:  Maurizio Sanguinetti; Brunella Posteraro
Journal:  Mycopathologia       Date:  2014-07-08       Impact factor: 2.574

Review 5.  Invasive fungal infections in transplant recipients.

Authors:  Jose A Vazquez; Marisa H Miceli; George Alangaden
Journal:  Ther Adv Infect Dis       Date:  2013-06

6.  Evaluation of Etest performed in Mueller-Hinton agar supplemented with glucose for antifungal susceptibility testing of clinical isolates of filamentous fungi.

Authors:  E Pinto; M Lago; L Branco; L A Vale-Silva; M D Pinheiro
Journal:  Mycopathologia       Date:  2014-02-26       Impact factor: 2.574

7.  Performance of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Aspergillus, Scedosporium, and Fusarium spp. in the Australian Clinical Setting.

Authors:  Sue Sleiman; Catriona L Halliday; Belinda Chapman; Mitchell Brown; Joanne Nitschke; Anna F Lau; Sharon C-A Chen
Journal:  J Clin Microbiol       Date:  2016-06-01       Impact factor: 5.948

8.  Mycoses in northeastern Brazil: epidemiology and prevalence of fungal species in 8 years of retrospective analysis in Alagoas.

Authors:  Fernanda Cristina de Albuquerque Maranhão; Jorge Belém Oliveira-Júnior; Maria Anilda Dos Santos Araújo; Denise Maria Wanderlei Silva
Journal:  Braz J Microbiol       Date:  2019-05-28       Impact factor: 2.476

9.  Fungal infection mimicking pulmonary malignancy: clinical and radiological characteristics.

Authors:  Marcos Duarte Guimarães; Edson Marchiori; Gustavo de Souza Portes Meirelles; Bruno Hochhegger; Pablo Rydz Pinheiro Santana; Jefferson Luiz Gross; Almir Galvão Vieira Bitencourt; Piyaporn Boonsirikamchai; Myrna Corbos Barco Godoy
Journal:  Lung       Date:  2013-09-17       Impact factor: 2.584

10.  Rare arthroconidial fungi in clinical samples: Scytalidium cuboideum and Arthropsis hispanica.

Authors:  Alejandra Giraldo; Deanna A Sutton; Josepa Gené; Annette W Fothergill; Josep Cano; Josep Guarro
Journal:  Mycopathologia       Date:  2012-10-17       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.